Triple-negative breast cancers (TNBCs) represent 10–20% of all breast cancers and are characterized by negative or low estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression1. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.